GeneWEAVE Sells to Roche for $425 Million

Palo Alto – August 21, 2015 – Cooley advised GeneWEAVE Biosciences on its approximately $425 million sale to Roche.

GeneWEAVE is a privately-held in vitro diagnostics company that is advancing clinical microbiology with diagnostic solutions. It helps healthcare providers in the fight against drug-resistant bacteria by enabling impactful surveillance programs, early therapy guidance and successful antibiotic stewardship. Roche Molecular Diagnostics is a subsidiary of F. Hoffman-La Roche, the world's largest biotech company.

The team advising GeneWEAVE included partners Mark Tanoury, Laura Medina and Barclay Kamb and associates Aaron Binstock, Kelsey Velemirovich and Carlton Fleming.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 850 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Mark Tanoury Partner, Palo Alto
Barclay Kamb Senior Counsel, Palo Alto
Laura Medina Partner, Colorado
Bill Boyle Paralegal Specialist, Palo Alto
Wendy Brenner Partner, Palo Alto
Leslie Cancel Special Counsel, San Francisco
Renee Deming Retired Partner, Palo Alto
Mark Windfeld-Hansen Partner, Palo Alto
Aaron Binstock Partner, Washington, DC
Carlton Fleming Partner, Palo Alto
Todd Gluth Partner, San Diego